WO2022052886A1 - Cd73抑制剂及其在医药上的应用 - Google Patents
Cd73抑制剂及其在医药上的应用 Download PDFInfo
- Publication number
- WO2022052886A1 WO2022052886A1 PCT/CN2021/116696 CN2021116696W WO2022052886A1 WO 2022052886 A1 WO2022052886 A1 WO 2022052886A1 CN 2021116696 W CN2021116696 W CN 2021116696W WO 2022052886 A1 WO2022052886 A1 WO 2022052886A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkylene
- compound
- alkyl
- reaction
- synthesis
- Prior art date
Links
- 0 C*(C)C(C*(C)*)c1c(*)nnc(C)c1C Chemical compound C*(C)C(C*(C)*)c1c(*)nnc(C)c1C 0.000 description 14
- LKGKUACPLXCVOF-UHFFFAOYSA-N COc1nc(OC)ncc1B(O)O Chemical compound COc1nc(OC)ncc1B(O)O LKGKUACPLXCVOF-UHFFFAOYSA-N 0.000 description 5
- XAXKZIUQIROVNV-UHFFFAOYSA-N Clc(nn1)cc(Br)c1Cl Chemical compound Clc(nn1)cc(Br)c1Cl XAXKZIUQIROVNV-UHFFFAOYSA-N 0.000 description 5
- IPWKHHSGDUIRAH-UHFFFAOYSA-N CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C Chemical compound CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 3
- OYPFTQDLBXIPDI-KOLCDFICSA-N Cc1c([C@@H](C2)[C@H]2C=O)cc(-c(cnc(OC)n2)c2OC)nn1 Chemical compound Cc1c([C@@H](C2)[C@H]2C=O)cc(-c(cnc(OC)n2)c2OC)nn1 OYPFTQDLBXIPDI-KOLCDFICSA-N 0.000 description 3
- CFMZSMGAMPBRBE-UHFFFAOYSA-N ON(C(c1c2cccc1)=O)C2=O Chemical compound ON(C(c1c2cccc1)=O)C2=O CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 3
- LFZJRTMTKGYJRS-UHFFFAOYSA-N C#Cc(cc1)ccc1Cl Chemical compound C#Cc(cc1)ccc1Cl LFZJRTMTKGYJRS-UHFFFAOYSA-N 0.000 description 1
- UEXCJVNBTNXOEH-UHFFFAOYSA-N C#Cc1ccccc1 Chemical compound C#Cc1ccccc1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 1
- JFDMLXYWGLECEY-UHFFFAOYSA-N C(C1OC1)c1ccccc1 Chemical compound C(C1OC1)c1ccccc1 JFDMLXYWGLECEY-UHFFFAOYSA-N 0.000 description 1
- LNWZCIWWFNUBNF-UHFFFAOYSA-N CC(B1OC(C)(C)C(C)(C)O1)Cl Chemical compound CC(B1OC(C)(C)C(C)(C)O1)Cl LNWZCIWWFNUBNF-UHFFFAOYSA-N 0.000 description 1
- DJYHCUCLVZLIOU-AEFFLSMTSA-N CC(C)c(cc1)cc(C(N2OC([C@@H](C3)[C@H]3c3ccccc3)=O)=O)c1C2=O Chemical compound CC(C)c(cc1)cc(C(N2OC([C@@H](C3)[C@H]3c3ccccc3)=O)=O)c1C2=O DJYHCUCLVZLIOU-AEFFLSMTSA-N 0.000 description 1
- OXZUHSZKOFUBFW-UHFFFAOYSA-N CC(C1)C1c1ccccc1 Chemical compound CC(C1)C1c1ccccc1 OXZUHSZKOFUBFW-UHFFFAOYSA-N 0.000 description 1
- QDYLTXCGHITYRU-ALCCZGGFSA-N CC/C(/C)=N\N=C Chemical compound CC/C(/C)=N\N=C QDYLTXCGHITYRU-ALCCZGGFSA-N 0.000 description 1
- PTVXZOZMWVSOOR-MDZDMXLPSA-N CC1(C)OB(/C=C/c(cc2)ccc2C#N)OC1(C)C Chemical compound CC1(C)OB(/C=C/c(cc2)ccc2C#N)OC1(C)C PTVXZOZMWVSOOR-MDZDMXLPSA-N 0.000 description 1
- MYKJZXRWDIWMDR-MDZDMXLPSA-N CC1(C)OB(/C=C/c2cc(OC)ccc2)OC1(C)C Chemical compound CC1(C)OB(/C=C/c2cc(OC)ccc2)OC1(C)C MYKJZXRWDIWMDR-MDZDMXLPSA-N 0.000 description 1
- JMNVNIDLBAPUEI-CMDGGOBGSA-N CC1(C)OB(/C=C/c2cccc(C#N)c2)OC1(C)C Chemical compound CC1(C)OB(/C=C/c2cccc(C#N)c2)OC1(C)C JMNVNIDLBAPUEI-CMDGGOBGSA-N 0.000 description 1
- ARAINKADEARZLZ-ZHACJKMWSA-N CC1(C)OB(/C=C/c2ccccc2)OC1(C)C Chemical compound CC1(C)OB(/C=C/c2ccccc2)OC1(C)C ARAINKADEARZLZ-ZHACJKMWSA-N 0.000 description 1
- JKNNTNSSKRNSCT-UHFFFAOYSA-N CC1(C)OB(B2[O](C)C(C)(C)C(C)(C)O2)OC1(C)C Chemical compound CC1(C)OB(B2[O](C)C(C)(C)C(C)(C)O2)OC1(C)C JKNNTNSSKRNSCT-UHFFFAOYSA-N 0.000 description 1
- NFQOWVDGZDIUQN-UHFFFAOYSA-N CC1(C)OB(C(C2)C2C=C)OC1(C)C Chemical compound CC1(C)OB(C(C2)C2C=C)OC1(C)C NFQOWVDGZDIUQN-UHFFFAOYSA-N 0.000 description 1
- UMTPNFKBXWFZJU-UHFFFAOYSA-N CC1(C)OB(C(C2)C2c(cc2)ccc2C#N)OC1(C)C Chemical compound CC1(C)OB(C(C2)C2c(cc2)ccc2C#N)OC1(C)C UMTPNFKBXWFZJU-UHFFFAOYSA-N 0.000 description 1
- YLQVKQUPCWFSFO-UHFFFAOYSA-N CC1(C)OB(C(C2)C2c(cc2)ccc2Cl)OC1(C)C Chemical compound CC1(C)OB(C(C2)C2c(cc2)ccc2Cl)OC1(C)C YLQVKQUPCWFSFO-UHFFFAOYSA-N 0.000 description 1
- RMPZNJCMFGYSJW-UHFFFAOYSA-N CC1(C)OB(C(C2)C2c2cc(C#N)ccc2)OC1(C)C Chemical compound CC1(C)OB(C(C2)C2c2cc(C#N)ccc2)OC1(C)C RMPZNJCMFGYSJW-UHFFFAOYSA-N 0.000 description 1
- ZLXTXZXIDZUZPS-UHFFFAOYSA-N CC1(C)OB(C(C2)C2c2cc(OC)ccc2)OC1(C)C Chemical compound CC1(C)OB(C(C2)C2c2cc(OC)ccc2)OC1(C)C ZLXTXZXIDZUZPS-UHFFFAOYSA-N 0.000 description 1
- UANSPBMADSQCLG-UHFFFAOYSA-N CC1(C)OB(C(C2)C2c2ccccc2)OC1(C)C Chemical compound CC1(C)OB(C(C2)C2c2ccccc2)OC1(C)C UANSPBMADSQCLG-UHFFFAOYSA-N 0.000 description 1
- UANSPBMADSQCLG-OLZOCXBDSA-N CC1(C)OB([C@@H](C2)[C@H]2c2ccccc2)OC1(C)C Chemical compound CC1(C)OB([C@@H](C2)[C@H]2c2ccccc2)OC1(C)C UANSPBMADSQCLG-OLZOCXBDSA-N 0.000 description 1
- AIDOCZIFPMXXEC-UHFFFAOYSA-N CCC(C1)C1c(cc1)ccc1Cl Chemical compound CCC(C1)C1c(cc1)ccc1Cl AIDOCZIFPMXXEC-UHFFFAOYSA-N 0.000 description 1
- IOBXAMISSWEGQH-UHFFFAOYSA-N CCC(C1)C1c1ccccc1 Chemical compound CCC(C1)C1c1ccccc1 IOBXAMISSWEGQH-UHFFFAOYSA-N 0.000 description 1
- CSWXDJJHNDBVQV-JRUYECLLSA-N CCC1C(OC)=NN[C@H]1[C@@H](C)CN/C(/OC)=N\C=C Chemical compound CCC1C(OC)=NN[C@H]1[C@@H](C)CN/C(/OC)=N\C=C CSWXDJJHNDBVQV-JRUYECLLSA-N 0.000 description 1
- NCYNGTINHYWJJQ-SVFXKOTRSA-N CCCC/C=N\C(OC)=N Chemical compound CCCC/C=N\C(OC)=N NCYNGTINHYWJJQ-SVFXKOTRSA-N 0.000 description 1
- VGNRLIUVXNITAZ-UHFFFAOYSA-N CO/C(/NCCl)=N/C=C Chemical compound CO/C(/NCCl)=N/C=C VGNRLIUVXNITAZ-UHFFFAOYSA-N 0.000 description 1
- CHJVWWFLSYJNGZ-UHFFFAOYSA-N COc(nc(nc1)OC)c1-c(nn1)cc(C(C2)C2c(cc2)ccc2C#N)c1Cl Chemical compound COc(nc(nc1)OC)c1-c(nn1)cc(C(C2)C2c(cc2)ccc2C#N)c1Cl CHJVWWFLSYJNGZ-UHFFFAOYSA-N 0.000 description 1
- PMHVDUQHWMFMER-UHFFFAOYSA-N COc(nc(nc1)OC)c1-c(nn1)cc(C(C2)C2c(cc2)ccc2Cl)c1Cl Chemical compound COc(nc(nc1)OC)c1-c(nn1)cc(C(C2)C2c(cc2)ccc2Cl)c1Cl PMHVDUQHWMFMER-UHFFFAOYSA-N 0.000 description 1
- AFBBCXYMFPQTQK-UHFFFAOYSA-N COc(nc(nc1)OC)c1-c(nn1)cc(C(C2)C2c2cc(C#N)ccc2)c1Cl Chemical compound COc(nc(nc1)OC)c1-c(nn1)cc(C(C2)C2c2cc(C#N)ccc2)c1Cl AFBBCXYMFPQTQK-UHFFFAOYSA-N 0.000 description 1
- PDLKDTGVEGFESC-IUCAKERBSA-N COc(nc(nc1)OC)c1-c(nn1)cc([C@@H](C2)[C@H]2C#C)c1Cl Chemical compound COc(nc(nc1)OC)c1-c(nn1)cc([C@@H](C2)[C@H]2C#C)c1Cl PDLKDTGVEGFESC-IUCAKERBSA-N 0.000 description 1
- LJRIVXJZDSBPAP-GJZGRUSLSA-N COc(nc(nc1)OC)c1-c(nn1)cc([C@@H](C2)[C@H]2C#Cc2ccccc2)c1Cl Chemical compound COc(nc(nc1)OC)c1-c(nn1)cc([C@@H](C2)[C@H]2C#Cc2ccccc2)c1Cl LJRIVXJZDSBPAP-GJZGRUSLSA-N 0.000 description 1
- DUXBAPGWRIVVAB-UHFFFAOYSA-N COc1c(C(C2)C2c2ccccc2)cc(C(C(N2)=O)=CNC2=O)nn1 Chemical compound COc1c(C(C2)C2c2ccccc2)cc(C(C(N2)=O)=CNC2=O)nn1 DUXBAPGWRIVVAB-UHFFFAOYSA-N 0.000 description 1
- DAOGDJLZZWUDNW-UHFFFAOYSA-N COc1cc(C(C2)C2c(cc(-c(c(OC)n2)cnc2OC)nn2)c2Cl)ccc1 Chemical compound COc1cc(C(C2)C2c(cc(-c(c(OC)n2)cnc2OC)nn2)c2Cl)ccc1 DAOGDJLZZWUDNW-UHFFFAOYSA-N 0.000 description 1
- QLQAMHIRKSXWGI-UHFFFAOYSA-N COc1cc(C(C2)C2c(cc(C(C(N2)=O)=CNC2=O)nn2)c2Cl)ccc1 Chemical compound COc1cc(C(C2)C2c(cc(C(C(N2)=O)=CNC2=O)nn2)c2Cl)ccc1 QLQAMHIRKSXWGI-UHFFFAOYSA-N 0.000 description 1
- SOLLLXJRYAHJMC-UHFFFAOYSA-N COc1cccc(C(C2)C2c(cc(nn2)Cl)c2Cl)c1 Chemical compound COc1cccc(C(C2)C2c(cc(nn2)Cl)c2Cl)c1 SOLLLXJRYAHJMC-UHFFFAOYSA-N 0.000 description 1
- ZZRLZNUXLGRWLU-PWSUYJOCSA-N COc1nc(OC)ncc1-c(nn1)cc([C@@H](C2)[C@H]2c2nc(cccc3)c3[nH]2)c1Cl Chemical compound COc1nc(OC)ncc1-c(nn1)cc([C@@H](C2)[C@H]2c2nc(cccc3)c3[nH]2)c1Cl ZZRLZNUXLGRWLU-PWSUYJOCSA-N 0.000 description 1
- SORYIEFTUZVAJG-UHFFFAOYSA-N CS=1=CN=NC=CC=1 Chemical compound CS=1=CN=NC=CC=1 SORYIEFTUZVAJG-UHFFFAOYSA-N 0.000 description 1
- WGEONMASLUCOSH-MSWICVQKSA-N C[C@@H](CNN=C)/N=C(\N=C(/C)\OC)/OC Chemical compound C[C@@H](CNN=C)/N=C(\N=C(/C)\OC)/OC WGEONMASLUCOSH-MSWICVQKSA-N 0.000 description 1
- ZJJNMXUSBPHRDY-UHFFFAOYSA-N Cc(nnc(-c(c(OC)n1)cnc1OC)c1)c1Cl Chemical compound Cc(nnc(-c(c(OC)n1)cnc1OC)c1)c1Cl ZJJNMXUSBPHRDY-UHFFFAOYSA-N 0.000 description 1
- DIIQCFKDDLFYDV-KOLCDFICSA-N Cc1c([C@@H](C2)[C@H]2C=C(F)F)cc(-c(c(OC)n2)cnc2OC)nn1 Chemical compound Cc1c([C@@H](C2)[C@H]2C=C(F)F)cc(-c(c(OC)n2)cnc2OC)nn1 DIIQCFKDDLFYDV-KOLCDFICSA-N 0.000 description 1
- PBNSLCCWLCAVCP-APPZFPTMSA-N Cc1c([C@@H](C2)[C@H]2C=C(F)F)cc(C(C(N2)=O)=CNC2=O)nn1 Chemical compound Cc1c([C@@H](C2)[C@H]2C=C(F)F)cc(C(C(N2)=O)=CNC2=O)nn1 PBNSLCCWLCAVCP-APPZFPTMSA-N 0.000 description 1
- UYKOYDZTERDASF-KOLCDFICSA-N Cc1c([C@@H]2[C@@H](CO)C2)cc(-c(cnc(OC)n2)c2OC)nn1 Chemical compound Cc1c([C@@H]2[C@@H](CO)C2)cc(-c(cnc(OC)n2)c2OC)nn1 UYKOYDZTERDASF-KOLCDFICSA-N 0.000 description 1
- LDZYRENCLPUXAX-UHFFFAOYSA-N Cc1nc(cccc2)c2[nH]1 Chemical compound Cc1nc(cccc2)c2[nH]1 LDZYRENCLPUXAX-UHFFFAOYSA-N 0.000 description 1
- DJMRHLQSIQWHAZ-UHFFFAOYSA-N Clc(nn1)cc(C(C2)C2c2ccccc2)c1Cl Chemical compound Clc(nn1)cc(C(C2)C2c2ccccc2)c1Cl DJMRHLQSIQWHAZ-UHFFFAOYSA-N 0.000 description 1
- OYWBUNMPWAVRFT-UHFFFAOYSA-N Clc1ccc(C(C2)C2c(cc(nn2)Cl)c2Cl)cc1 Chemical compound Clc1ccc(C(C2)C2c(cc(nn2)Cl)c2Cl)cc1 OYWBUNMPWAVRFT-UHFFFAOYSA-N 0.000 description 1
- RXMXTGXIGWJQKA-UHFFFAOYSA-N N#Cc1ccc(C(C2)C2c(cc(C(C(N2)=O)=CNC2=O)nn2)c2Cl)cc1 Chemical compound N#Cc1ccc(C(C2)C2c(cc(C(C(N2)=O)=CNC2=O)nn2)c2Cl)cc1 RXMXTGXIGWJQKA-UHFFFAOYSA-N 0.000 description 1
- XVDIJVLBSINIFO-UHFFFAOYSA-N N#Cc1ccc(C(C2)C2c(cc(nn2)Cl)c2Cl)cc1 Chemical compound N#Cc1ccc(C(C2)C2c(cc(nn2)Cl)c2Cl)cc1 XVDIJVLBSINIFO-UHFFFAOYSA-N 0.000 description 1
- BAEMKWZHORWPFR-UHFFFAOYSA-N N#Cc1cccc(C(C2)C2c(cc(C(C(N2)=O)=CNC2=O)nn2)c2Cl)c1 Chemical compound N#Cc1cccc(C(C2)C2c(cc(C(C(N2)=O)=CNC2=O)nn2)c2Cl)c1 BAEMKWZHORWPFR-UHFFFAOYSA-N 0.000 description 1
- HCLUKHYIXZUMPT-UHFFFAOYSA-N N#Cc1cccc(C(C2)C2c(cc(nn2)Cl)c2Cl)c1 Chemical compound N#Cc1cccc(C(C2)C2c(cc(nn2)Cl)c2Cl)c1 HCLUKHYIXZUMPT-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N Nc(cccc1)c1N Chemical compound Nc(cccc1)c1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- YPRQRHQKCLDAGB-UHFFFAOYSA-N O=C(C(c(nn1)cc(C(C2)C2c2ccccc2)c1Cl)=CN1)NC1=O Chemical compound O=C(C(c(nn1)cc(C(C2)C2c2ccccc2)c1Cl)=CN1)NC1=O YPRQRHQKCLDAGB-UHFFFAOYSA-N 0.000 description 1
- JNBWATBEZSZBJP-STQMWFEESA-N O=C(C(c(nn1)cc([C@@H](C2)[C@H]2C#Cc2ccccc2)c1Cl)=CN1)NC1=O Chemical compound O=C(C(c(nn1)cc([C@@H](C2)[C@H]2C#Cc2ccccc2)c1Cl)=CN1)NC1=O JNBWATBEZSZBJP-STQMWFEESA-N 0.000 description 1
- CQWVECPLGDOJHO-SCZZXKLOSA-N O=C(C(c(nn1)cc([C@@H](C2)[C@H]2c2nc(C=CCC3)c3[nH]2)c1Cl)=CN1)NC1=O Chemical compound O=C(C(c(nn1)cc([C@@H](C2)[C@H]2c2nc(C=CCC3)c3[nH]2)c1Cl)=CN1)NC1=O CQWVECPLGDOJHO-SCZZXKLOSA-N 0.000 description 1
- YPRQRHQKCLDAGB-WDEREUQCSA-N O=C(C(c(nn1)cc([C@H](C2)[C@@H]2c2ccccc2)c1Cl)=CN1)NC1=O Chemical compound O=C(C(c(nn1)cc([C@H](C2)[C@@H]2c2ccccc2)c1Cl)=CN1)NC1=O YPRQRHQKCLDAGB-WDEREUQCSA-N 0.000 description 1
- SEPKAHIKIAFOTO-UHFFFAOYSA-N O=C(C1C(Cc2ccccc2)C1)ON(C(c1c2cccc1)=O)C2=O Chemical compound O=C(C1C(Cc2ccccc2)C1)ON(C(c1c2cccc1)=O)C2=O SEPKAHIKIAFOTO-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N O=C(c1c2cccc1)NC2=O Chemical compound O=C(c1c2cccc1)NC2=O XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- NHRRSNXEZMRFKC-UHFFFAOYSA-N OC(C1C(Cc2ccccc2)C1)=O Chemical compound OC(C1C(Cc2ccccc2)C1)=O NHRRSNXEZMRFKC-UHFFFAOYSA-N 0.000 description 1
- AHDDRJBFJBDEPW-BDAKNGLRSA-N OC([C@@H](C1)[C@H]1c1ccccc1)=O Chemical compound OC([C@@H](C1)[C@H]1c1ccccc1)=O AHDDRJBFJBDEPW-BDAKNGLRSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Definitions
- the present invention relates to a CD73 inhibitor having cancer therapeutic activity.
- the present invention also relates to methods for the preparation of these compounds and pharmaceutical compositions containing them.
- Extracellular 5'-nucleotidase is a cell membrane glycoprotein that exists on the cell membrane surface of a variety of cell types, including endothelial cells, lymphocytes, stromal cells, and tumor cells Wait.
- CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis.
- CD73 can also promote tumorigenesis through non-immune-related mechanisms, such as promoting tumor angiogenesis and promoting tumor cell adhesion to extracellular matrix proteins.
- high CD73 expression is associated with lymph node metastasis and poor prognosis in multiple cancer types, and CD73 has been found to be an independent prognostic factor in prostate cancer and triple-negative breast cancer patients.
- CD73 Drugs targeting CD73 have become one of the hot spots in current drug research and development, and some varieties have entered the clinical stage.
- the products under development include both macromolecular antibodies and small molecule drugs.
- the present invention will provide a novel structure of small molecule CD73 inhibitor with good antitumor activity.
- the present invention provides a compound represented by general formula (I), its tautomer, deuterated substance or pharmaceutically acceptable salt:
- Ring A is selected from C 6-14 aryl or 5-14 membered heteroaryl; the C 6-14 aryl or 5-14 membered heteroaryl is optionally substituted by 1 or more R 6 ;
- R 1 are each independently selected from H, halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy or C 1-3 haloalkyl, preferably H;
- R 2 is selected from H, halogen, cyano, substituted or unsubstituted C 1-3 alkyl, substituted or unsubstituted C 1-3 alkoxy, substituted or unsubstituted C 2-4 alkenyl, substituted or unsubstituted C 2-4 alkynyl;
- R4 is selected from H, halogen or methyl ;
- Each R a is independently selected from H, halogen, hydroxy, amino, oxo, nitro, cyano, carboxyl, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 aminoalkane base, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 heteroalkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 6-14 aryl or 5-14 membered heteroaryl;
- n is selected from 0, 1, 2, 3 or 4;
- n is selected from 0 or 1;
- the present invention provides a compound, its tautomer, deuterated product or pharmaceutically acceptable salt, characterized in that it is selected from the compound of formula (IA) or formula (IA-1):
- L is selected from bond, C 2-6 alkenyl or C 2-6 alkynyl; said C 2-6 alkenyl or C 2-6 alkynyl is optionally substituted by 1 or more R 5 ;
- Ring A is selected from C 6-14 aryl or 5-14 membered heteroaryl, said C 6-14 aryl or 5-14 membered heteroaryl optionally substituted by 1 or more R 6 ;
- Each R a is independently selected from H, halogen, hydroxy, amino, oxo, nitro, cyano, carboxyl, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 aminoalkane base, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 heteroalkyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 6-14 aryl or 5-14 membered heteroaryl;
- R 2 is selected from H, halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, C 2-4 alkenyl or C 2-4 alkynyl;
- R4 is selected from H, halogen or methyl.
- the present invention provides a compound, its tautomer, deuterated product or pharmaceutically acceptable salt, characterized in that, L is selected from a bond, vinyl or ethynyl, and the vinyl or ethynyl is optionally replaced by one or A plurality of R 5 is substituted; preferably L is selected from bond, vinyl or ethynyl, more preferably L is bond.
- the present invention provides a compound, its tautomer, deuterated product or pharmaceutically acceptable salt, characterized in that ring A is selected from Ring A may optionally also be substituted with one or more R 6 ; preferably Ring A is phenyl or pyridyl.
- the present invention provides a compound, its tautomer, deuterated product or pharmaceutically acceptable salt, characterized in that it is selected from the compound of formula (IB) or formula (IB-1):
- R 1 , R 2 and R 4 are as defined in formula (I).
- the present invention provides a compound, its tautomer, deuterated product or pharmaceutically acceptable salt, characterized in that R 2 is selected from H, halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy or vinyl, preferably H, chlorine, cyano, methyl, methoxy or vinyl, more preferably chlorine, cyano, methyl or methoxy.
- the present invention provides a compound, its tautomer, deuterated product or pharmaceutically acceptable salt, characterized in that R 4 is H.
- the present invention provides a compound, its tautomer, deuterated substance or pharmaceutically acceptable salt, which is selected from:
- the present invention provides a pharmaceutical composition, characterized in that the pharmaceutical composition contains a therapeutically effective amount of the compound of formula (I), its tautomer, deuterated substance or a pharmaceutically acceptable salt and at least one pharmaceutical acceptable excipients.
- the present invention provides the application of a compound of formula (I), its tautomer, deuterated compound or pharmaceutically acceptable salt or its pharmaceutical composition in the preparation of medicines; preferably in the preparation of cancer therapeutic medicines.
- the present invention provides a method of treating and/or preventing a disease, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutical composition thereof; preferably a method of treating and/or preventing cancer.
- the present invention provides a pharmaceutical combination comprising the compound of formula (I), its tautomer, deuterated compound or a pharmaceutically acceptable salt thereof, and an anti-PD-L(1) antibody.
- the present invention provides a kind of method for preparing the compound of general formula (ID), its tautomer, deuterated substance or pharmaceutically acceptable salt, the method comprises:
- R 1 -R 2 , R 4 , Q, m, and n are as described in formula (I).
- the application is in the preparation of a drug targeting CD73.
- the application is in the preparation of a drug for treating and/or preventing cancer.
- the cancer is selected from breast cancer, multiple myeloma, bladder cancer, endometrial cancer, gastric cancer, cervical cancer, rhabdomyosarcoma, non-small cell lung cancer, small cell lung cancer, pleomorphic lung cancer, ovarian cancer, esophagus Carcinoma, melanoma, colorectal cancer, hepatoma, head and neck tumor, hepatocholangiocarcinoma, myelodysplastic syndrome, glioblastoma, prostate cancer, thyroid cancer, Schwann cell tumor, lung squamous cell Carcinoma, lichenoid keratosis, synovial sarcoma, skin cancer, pancreatic cancer, testicular cancer, or liposarcoma.
- the present invention also provides a method for treating and/or preventing a disease, comprising administering a therapeutically effective amount of at least any compound represented by structural formula (I) or a pharmaceutical composition containing the same to a treatment subject.
- the present invention also provides a method for treating cancer, comprising administering a therapeutically effective amount of at least any compound represented by the structural formula (I) or a pharmaceutical composition containing the same to a treatment subject.
- halogen refers to fluorine, chlorine, bromine or iodine.
- alkyl includes linear or branched monovalent saturated hydrocarbon groups.
- alkyl includes methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 3-(2-methyl)butyl, 2 -pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-hexyl, 2-methylpentyl, etc.
- " 1-6 " in " C1-6 alkyl” refers to groups containing 1, 2, 3, 4, 5 or 6 carbon atoms arranged in straight or branched chain form.
- Heteroalkyl means that one carbon atom on an alkyl group is replaced by a heteroatom, including N, S or O.
- Alkylene is meant to include straight or branched divalent saturated hydrocarbon groups. For example methylene, 1,2-ethylene, 1,3-propylene or 1,2-isopropylene. Similarly, “ 1-6 " in “ C1-6 alkylene” refers to groups containing 1, 2, 3, 4, 5 or 6 carbon atoms arranged in straight or branched chain form.
- Alkoxy refers to the oxyether form of the aforementioned straight or branched chain alkyl groups, ie, -O-alkyl.
- compositions comprising "a” pharmaceutically acceptable excipient can be interpreted to mean that the composition includes “one or more” pharmaceutically acceptable excipients.
- aryl in the present invention, unless otherwise specified, refers to an unsubstituted or substituted mono- or fused-ring aromatic group comprising atoms of a carbocyclic ring.
- the aryl group is a 6- to 14-membered monocyclic or fused-ring aromatic group.
- the aryl group is a 6- to 10-membered monocyclic or bicyclic aromatic ring group.
- Preferred are phenyl and naphthyl. Most preferred is phenyl.
- the aryl ring can be fused to a heteroaryl, heterocyclyl, or cycloalkyl, wherein the ring attached to the parent structure is an aryl ring, non-limiting examples including, but not limited to, benzocyclopentyl.
- heterocyclyl in the present invention, unless otherwise specified, refers to an unsubstituted or substituted 3-14 membered stable monolayer consisting of carbon atoms and 1-3 heteroatoms selected from N, O or S. Ring systems, which are saturated or partially unsaturated monocyclic or polycyclic 14-membered cyclic hydrocarbon substituents comprising 3 to 14 carbon atoms, wherein nitrogen or sulfur heteroatoms can be selectively oxidized, and nitrogen heteroatoms can be Selectively quaternized.
- the heterocyclyl group can be attached to any heteroatom or carbon atom to form a stable structure.
- heterocyclyl groups include, but are not limited to, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidyl, tetrahydrofuranyl, dioxolanyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydrooxazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone and tetrahydro oxadiazolyl.
- the heterocyclyl group can be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring attached to the parent structure is a heterocyclyl group.
- heteroaryl in the present invention, unless otherwise specified, refers to an unsubstituted or substituted stable 5- or 6-membered monocyclic aromatic ring system or an unsubstituted or substituted 9- to 14-membered fused
- Heteroaryl groups can be attached to any heteroatom or carbon atom to form a stable structure.
- heteroaryl groups include, but are not limited to, thienyl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridyl Azinyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzothiazolyl, benzothiazolyl, benzene thiadiazolyl, benzotriazolyl adenine, quinolinyl or isoquinolinyl.
- the heteroaryl group can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring attached to the parent structure is a heteroaryl ring.
- cycloalkyl refers to a cyclic saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent having 3 to 14 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl .
- the cycloalkyl group can be fused to an aryl, heterocyclyl or heteroaryl ring, wherein the ring attached to the parent structure is a cycloalkyl group.
- substituted refers to the replacement of one or more hydrogen atoms in a group with the same or a different substituent, respectively.
- substituents include, but are not limited to, H, cyano, halogen, C 1-6 alkyl, C 1-6 haloalkyl, -C 0-6 alkylene-OR a , -C 0-6 alkylene- OC(O)N(R a ) 2 , -C 0-6 alkylene-N(R a ) 2 , -C 0-6 alkylene-NR a C(O)R a , -C 0-6 Alkylene-NR a C(O)N(R a ) 2 , -C 0-6 alkylene-NR a S(O)R a , -C 0-6 alkylene-NR a S(O)R a , -C 0-6 alkylene-NR a S(O) 2 R a , -C 0-6 al
- the substituents are independently selected from the group consisting of -F, -Cl, -Br, -I, -OH, trifluoromethoxy, ethoxy, propoxy, isopropoxy, n-butoxy group, isobutoxy, tert-butoxy, -SCH 3 , -SC 2 H 5 , carboxaldehyde, -C(OCH 3 ), cyano, nitro, -CF 3 , -OCF 3 , amino, dimethyl amino, methylthio, sulfonyl and acetyl groups.
- substituted alkyl groups include, but are not limited to, 2,3-dihydroxypropyl, 2-aminoethyl, 2-hydroxyethyl, pentachloroethyl, trifluoromethyl, methoxymethyl, pentafluoroethyl , phenylmethyl, dioxinylmethyl and piperazinylmethyl.
- substituted alkoxy groups include, but are not limited to, 2-hydroxyethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2-methoxyethoxy, 2-aminoethoxy, 2,3-dihydroxypropoxy, cyclopropylmethoxy, aminomethoxy, trifluoromethoxy, 2-diethylaminoethoxy, 2-ethoxycarbonylethoxy, 3- Hydroxypropoxy.
- pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
- acids their corresponding salts can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic and organic bases.
- bases their corresponding salts can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
- the compound represented by formula (I) will be used as a medicine, it is preferable to use a certain purity, for example, at least 60% pure, more suitably at least 75% pure, particularly suitably at least 98% pure (% by weight) Compare).
- Prodrugs of the compounds of the present invention are included within the scope of the present invention.
- the prodrugs refer to functional derivatives that are readily converted into the desired compound in vivo.
- any pharmaceutically acceptable salt, ester, salt of ester or other derivative of a compound of the present application which, upon administration to a recipient, is capable of providing, directly or indirectly, a compound of the present application or a pharmaceutically active metabolite thereof or Residues.
- the compounds of the present invention may contain one or more asymmetric centers and may thereby give rise to diastereomers and optical isomers.
- the present invention includes all possible diastereomers and racemic mixtures thereof, substantially pure resolved enantiomers thereof, all possible geometric isomers and pharmaceutically acceptable salts thereof.
- the present invention includes any possible tautomer and pharmaceutically acceptable salts thereof, and mixtures thereof.
- substitution of compounds of formula (I) with heavier isotopes may provide certain therapeutic advantages due to greater metabolic stability, eg increased in vivo half-life or reduced dosage requirements.
- the present invention includes any possible solvates and polymorphs.
- the type of solvent that forms the solvate is not particularly limited as long as the solvent is pharmaceutically acceptable.
- water, ethanol, propanol, acetone and similar solvents can be used.
- composition refers to a product comprising a specified amount of each of the specified ingredients, as well as any product produced directly or indirectly from a combination of the specified amounts of each of the specified ingredients. Accordingly, pharmaceutical compositions containing the compounds of the present invention as active ingredients and methods of preparing the compounds of the present invention are also part of the present invention.
- the pharmaceutical composition provided by the present invention comprises a compound represented by formula (I) (or a pharmaceutically acceptable salt thereof) as an active component, a pharmaceutically acceptable excipient and other optional therapeutic components or Accessories.
- the pharmaceutical compositions of the present invention include oral, rectal, topical and Pharmaceutical compositions for parenteral (including subcutaneous, intramuscular, intravenous) administration.
- the pharmaceutical compositions of the present invention may conveniently be presented in unit dosage form and prepared by any of the methods of preparation well known in the art of pharmacy.
- the present invention will further illustrate the technical solutions of the present invention with the following examples.
- the following examples are only used to illustrate the specific embodiments of the present invention, so that those skilled in the art can understand the present invention, but are not intended to limit the protection scope of the present invention.
- the technical means or methods that are not particularly described are conventional technical means or methods in the field.
- the chiral compounds of the present invention can be resolved and purified by chiral synthesis or conventional chiral columns.
- n-BuLi n-butyl lithium
- Dioxane Dioxane
- DIEA or DIPEA N,N-diisopropylethylamine
- TFA trifluoroacetic acid
- TBSCl tert-butyldimethylsilyl chloride
- PCC pyridinium chlorochromate
- TBAF tetrabutylammonium fluoride trihydrate
- Pd(dppf)Cl 2 -CH 2 Cl 2 [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex;
- PE petroleum ether
- Xantphos 4,5-bisdiphenylphosphine-9,9-dimethylxanthene
- Pd(AcO) 2 palladium acetate
- Pd 2 (dba) 3 tris(dibenzylideneacetone)dipalladium
- Dess-Martin reagent Dess-Martin reagent
- Triethyl phosphoryl acetate (46.64 g) was dissolved in anhydrous 1,4-dioxane (60 mL), cooled to 0 °C, and n-BuLi (83.2 mL) was slowly added dropwise under nitrogen protection. Stir to room temperature for 0.5h. Add (R)-2-ethyloxirane (15.00 g), and stir at room temperature for 10 min. Then it was transferred to a stuffy tank, and the temperature was raised to 150° C. to react overnight.
- Triethyl phosphoryl acetate 34.20 g was dissolved in anhydrous 1,4-dioxane (30 mL), cooled to 0 °C, and n-BuLi (61.0 mL) was slowly added dropwise under nitrogen protection. Stir to room temperature for 0.5h. Epoxybutene (10.69 g) was added, and the mixture was stirred at room temperature for 10 min. Then it was transferred to a stuffy tank, and the temperature was raised to 150° C. to react overnight.
- step 1
- Triethyl phosphoryl acetate (8.35 g) was dissolved in anhydrous 1,4-dioxane (20 mL), cooled to 0 °C, and n-BuLi (14.9 mL) was slowly added dropwise under nitrogen protection. Stir to room temperature for 0.5h. 2-benzyl oxirane (5.00 g) was added, and the mixture was stirred at room temperature for 10 min. Then it was transferred to a stuffy tank, and the temperature was raised to 150° C. to react overnight.
- Triethyl phosphoryl acetate (77 g) and sodium tert-butoxide (33 g) were dissolved in anhydrous 1,4-dioxane (100 mL), cooled to 0 °C, stirred under nitrogen protection, warmed to room temperature and stirred for 0.5 h .
- Compound M6-1 (65 g) was added and stirred at room temperature for 10 min. Then it was transferred to a stuffy tank, and the temperature was raised to 150° C. to react overnight.
- Step 9 Compound M6 synthesis
- compound M8-2 In a 100mL three-necked flask, compound M8-2 (2.0g), (2,4-dimethoxypyrimidin-5-yl)boronic acid (1.2g), potassium carbonate (1.1g), [1,1'-bis( Diphenylphosphino)ferrocene]palladium dichloride (0.2g), dioxane (25mL), water (1.5mL), N 2 protection, react at 60°C for 0.5h.
- compound M8-2 2.0g
- (2,4-dimethoxypyrimidin-5-yl)boronic acid 1.2g
- potassium carbonate 1.1g
- [1,1'-bis( Diphenylphosphino)ferrocene]palladium dichloride 0.2g
- dioxane 25mL
- water 1.5mL
- N 2 protection react at 60°C for 0.5h.
- Triethyl phosphoryl acetate (62 g) and sodium tert-butoxide (26 g) were dissolved in anhydrous 1,4-dioxane (70 mL), cooled to 0 °C, stirred under nitrogen protection, warmed to room temperature and stirred for 0.5 h .
- Compound M11-1 (30 g) was added and stirred at room temperature for 10 min. Then it was transferred to a stuffy tank, and the temperature was raised to 150° C. to react overnight.
- Example 1 Compound 1 (5-(5-((1S,2S)-2-ethylcyclopropyl)-6-vinylpyridazin-3-yl)pyrimidine-2,4(1H,3H)- Synthesis of diketone)
- Methyltriphenylphosphine bromide (0.4g) was added to a 50mL three-necked flask, dissolved in anhydrous tetrahydrofuran (5mL), and potassium tert-butoxide (0.13g) was added under N2 protection at 0°C to react for 1h.
- Example 7 Compound 7 (5-(6-methyl-5-((1S,2R)-2-vinylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H)- Synthesis of diketone)
- Example 8 Compound 8 (5-(6-methyl-5-((1S,2R)-2-((E)-prop-1-en-1-yl)cyclopropyl)pyridazine-3- Synthesis of pyrimidine-2,4(1H,3H)-dione)
- Example 9 Compound 9 (5-(5-((1S,2R)-2-((E)-2-cyclopropylvinyl)cyclopropyl)-6-methyl-pyridazin-3-yl ) synthesis of pyrimidine-2,4(1H,3H)-dione)
- Example 10 Compound 10 ((E)-3-((1R,2S)-2-(6-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)- Synthesis of 3-Methylpyridazin-4-yl)cyclopropyl)acrylonitrile)
- Example 11 Compound 11 (5-(-5-((1S,2S)-2-(2,2-difluorovinyl)cyclopropyl)6-methylpyridazin-3-yl)pyrimidine-2 ,4(1H,3H)-Diketone) Synthesis
- Example 12 Compound 12 (5-(5-((1S,2S)-2-ethynylcyclopropyl)6-methylpyridazin-3-yl)pyrimidine-2,4(1H,3H)-di ketone) synthesis
- Example 13 Compound 13 (5-(6-Chloro-5-((1S,2R)-2-vinylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H)-di ketone) synthesis
- Example 14 Compound 14 (5-(6-Chloro-5-((1S,2S)-2-ethynylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H)-di ketone) synthesis
- Example 15 Compound 15 (6-(2,4-Dioxy-1,2,3,4-tetrahydropyrimidin-5-yl)-4-((1S,2S)-2-ethynylcyclopropane Synthesis of pyridazine-3-carbonitrile
- Example 16 Compound 16 (5-(6-methyl-5-((1S,2R)-2-((E)-styryl)cyclopropyl)pyridazin-3-yl)pyrimidine-2, Synthesis of 4(1H,3H)-dione)
- Example 17 Compound 17 (4-((E)-2-((1R,2S)-2-(3-chloro-6-(2,4-dioxo-1,2,3,4-tetrahydro) Synthesis of pyrimidin-5-yl)pyridazin-4-yl)cyclopropyl)vinyl)benzonitrile)
- Example 18 Compound 18 (5-(6-Chloro-5-((1S,2S)-2-(phenylethynyl)cyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H, Synthesis of 3H)-diketone)
- Example 19 Compound 19(3-((((1S,2S)-2-(3-chloro-6-(2,4-oxo-1,2,3,4-tetrahydropyrimidin-5-yl ) Synthesis of pyridazin-4-yl)cyclopropyl)ethynyl)benzonitrile)
- Example 20 Compound 20 (5-(6-Methoxy-5-((1S,2R)-2-((E)-styryl)cyclopropyl)pyridazin-3-yl)pyrimidine-2 ,4(1H,3H)-Diketone) Synthesis
- Example 21 Compound 21 (5-(6-Methoxy-5-((1S,2S)-2-(phenylethynyl)cyclopropyl)pyridazin-3-yl)pyrimidine-2,4( Synthesis of 1H,3H)-diketone)
- Example 24 Compound 24 (5-(6-chloro-5-(2-(p-tolyl)cyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H)-dione) synthesis
- Example 25 Compound 25 (4-(2-(3-Chloro-6-(2,4-dioxy-1,2,3,4-tetrahydropyrimidin-5-yl)pyridazin-4-yl) ) cyclopropyl) benzonitrile) synthesis
- Example 26 Compound 26 (3-(2-(3-Chloro-6-(2,4-dioxy-1,2,3,4-tetrahydropyrimidin-5-yl)pyridazin-4-yl) ) cyclopropyl) benzonitrile) synthesis
- Example 27 Compound 27 (5-(6-Chloro-5-(2-(4-fluorophenyl)cyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H)-dione )Synthesis
- Example 28 Compound 28 (5-(6-Chloro-5-(2-(4-chlorophenyl)cyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H)-dione )Synthesis
- Example 29 Compound 29 (5-(6-Chloro-5-(2-(3-methoxyphenyl)cyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H)- Synthesis of diketone)
- Example 30 Compound 30 (5-(6-Chloro-5-(2-(naphthalen-1-yl)cyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H)-dione )Synthesis
- Example 32 Compound 32 (5-(5-(2-(4-fluorophenyl)cyclopropyl)-6-methoxypyridazin-3-yl)pyrimidine-2,4(1H,3H)- Synthesis of diketone)
- Example 33 Compound 33 (5-(5-(2-(4-chlorophenyl)cyclopropyl)-6-methoxypyridazin-3-yl)pyrimidine-2,4(1H,3H)- Synthesis of diketone)
- Example 34 Compound 34 (6-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4-(2-phenylcyclopropyl)pyridazine-3 -formonitrile) synthesis
- Example 35 Compound 35 (6-(2,4-Dioxy-1,2,3,4-tetrahydropyrimidin-5-yl)-4-(2-(4-fluorophenyl)cyclopropyl) ) Synthesis of pyridazine-3-carbonitrile)
- Example 36 Compound 36 (4-(2-(4-chlorophenyl)cyclopropyl)-6-(2,4-dioxy-1,2,3,4-tetrahydropyrimidin-5-yl) ) Synthesis of pyridazine-3-carbonitrile)
- Example 37 Compound 37 (5-(6-Chloro-5-((1S,2S)-2-(pyridin-4-ylethynyl)cyclopropyl)pyridazin-3-yl)pyrimidine-2,4 Synthesis of (1H,3H)-dione)
- Example 38 Compound 38 (6-((((1S,2S)-2-(3-chloro-6-(2,4-oxo-1,2,3,4-tetrahydropyrimidin-5-yl ) Synthesis of pyridazin-4-yl)cyclopropyl)ethynyl)nicotinonitrile)
- Example 40 Compound 40 (4-((E)-2-((1R,2S)-2-(3-chloro-6-(2,4-dioxy-1,2,3,4-tetrakis) Synthesis of Hydropyrimidin-5-yl)pyridazin-4-yl)cyclopropyl)vinyl)benzonitrile)
- Example 41 Compound 41 (5-(6-methyl-5-((1S,2S)-2-(phenylethynyl)cyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H, Synthesis of 3H)-diketone)
- Examples 42-48 were synthesized using the methods of Example 18 above, or analogously using the corresponding intermediates.
- Examples 49-53 were synthesized using the method of Example 21 above, or analogously using the corresponding intermediates.
- Examples 54-56 were synthesized using the methods of Example 34 above, or analogous methods using the corresponding intermediates.
- Example 57 Compound 57 (5-(6-Chloro-5-((1S,2S)-2-phenylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H)-di ketone) synthesis
- Step 1 Synthesis of Compound 57-1
- reaction solution was poured into water, extracted with ethyl acetate, washed with saturated brine, dried and concentrated to obtain a crude product, which was purified by column chromatography to obtain a white solid crude product, the crude product was slurried with methanol, and suction filtered to obtain a white solid (0.6 g, 33.18% yield). Namely compound 57-2.
- Example 59 Synthesis of Compound 59 (5-(5-((1S,2S)-2-phenylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H)-dione)
- Step 1 Synthesis of Compound 59-1
- reaction solution was poured into water, extracted with ethyl acetate, washed with saturated brine, dried and concentrated to obtain a crude product, which was purified by column chromatography to obtain a white solid crude product, the crude product was slurried with methanol, and suction filtered to obtain a white solid (0.3 g, 69.00% yield). Namely compound 59-2.
- Example 60 Compound 60 (5-(5-((1S,2S)-2-(1H-benzo[d]imidazol-2-yl)cyclopropyl)-6-chloropyridin-3-yl)pyrimidine -2,4(1H,3H)-dione) Synthesis
- Examples 61-77 were synthesized using the method of Example 23 above, or analogously using the corresponding intermediates.
- Example 77 Compound 77 (4-(2-(6-(2,4-dioxy-1,2,3,4-tetrahydropyrimidin-5-yl)-3-methoxypyridazine-4 Synthesis of -yl)cyclopropyl)benzonitrile)
- Example 78 Compound 78 (4-(2-(4-cyanophenyl)cyclopropyl)-6-(2,4-dioxy-1,2,3,4-tetrahydropyrimidine-5 Synthesis of -yl)pyridazine-3-carbonitrile)
- Example 1 Detection of enzymatic activity at the cellular level
- Calu-6 cells were digested, resuspended in TM buffer (25 mM Tris, 5 mM MgCl 2 , pH 7.5), and plated in a 96-well plate at 25,000 cells and 100 ⁇ L/well.
- TM buffer was used to prepare compound solutions with gradient concentrations, and 50 ⁇ L of DMSO solutions of the compounds to be tested were added to the cells in each well. 0.3, 0 nM (the final concentration of DMSO is 0.625%).
- Pre-incubate for 30 min on a constant temperature horizontal shaker at 37 °C add 50 ⁇ L of 800 ⁇ M AMP solution to each well, and continue to incubate at 37 °C for 120 min on a constant temperature horizontal shaker, then centrifuge the 96-well plate and transfer 50 ⁇ L of supernatant per well to a new 96-well plate. , add 50 ⁇ L of 130 ⁇ M ATP solution and 100 ⁇ L of Cell-titer Glo working solution to each well, shake and mix, incubate at room temperature for 10 min, read the Luminescence luminescence value with a multi-function microplate reader, and convert the luminescence value reading into inhibition percentage:
- Max is the DMSO control.
- mice Using mice as the test animals, the LC/MS/MS method was used to determine the drug concentration in the plasma at different times after the mice were given the compounds of the examples by gavage. The pharmacokinetic behavior of the compound of the present invention in mice was studied, and its pharmacokinetic characteristics were evaluated.
- mice Use healthy Balb/C female mice (about 20 g) purchased from Weitong Lihua Laboratory Animal Co., Ltd. to conduct a single PK study in mice (PO 10 mg/kg). About 1 hour before administration, a certain amount of medicine was weighed, and 5% DMSO, 95% hydroxypropyl beta-cyclodextrin (HP- ⁇ -CD) solution was added to prepare a colorless and clear solution.
- HP- ⁇ -CD solution is a 20% HP- ⁇ -CD aqueous solution prepared by adding HP- ⁇ -CD powder to 0.9% physiological saline.
- the intragastric administration was administered at a dose of 10 mL/kg, and blood was collected from the orbital venous plexus of mice.
- the blood collection time points were as follows: 0.25, 0.5, 1.0, 2.0, 4.0, 7.0, 24.0 before administration and after administration. 100 uL of whole blood was collected at each time point to a K 2 EDTA anticoagulation tube, the collected whole blood samples were centrifuged at 4000 rpm for 10 minutes, and the plasma was separated and stored in a -80°C refrigerator.
Abstract
Description
化合物名称 | IC 50(nM) | 化合物名称 | IC 50(nM) |
1 | 21.6 | 42 | 4.4 |
2 | 329 | 43 | 3.7 |
3 | 721 | 44 | 3.1 |
4 | 22.6 | 45 | 1.5 |
6 | 50.7 | 46 | 4.4 |
7 | 21 | 47 | 7.8 |
8 | 92.7 | 48 | 3.8 |
9 | 200 | 49 | 5.5 |
10 | 31 | 50 | 12.6 |
11 | 46 | 51 | 4.3 |
12 | 19.8 | 52 | 5.8 |
13 | 8.5 | 53 | 2.4 |
14 | 28 | 54 | 8.2 |
15 | 8.8 | 55 | 5.6 |
16 | 2.3 | 56 | 19.4 |
17 | 2.3 | 57 | 1.3 |
18 | 5.6 | 59 | 9.9 |
19 | 2.99 | 60 | 23.3 |
20 | 1.2 | 61 | 19 |
21 | 5.5 | 62 | 5.6 |
22 | 22.7 | 63 | 19 |
23 | 1.4 | 64 | 22.3 |
24 | 5.2 | 65 | 4.7 |
25 | 1.8 | 66 | 3.9 |
26 | 8.7 | 67 | 7.3 |
27 | 1.8 | 68 | 15 |
28 | 2.7 | 69 | 13.4 |
29 | 4.1 | 70 | 7 |
30 | 60 | 71 | 4.6 |
31 | 4.2 | 72 | 4.9 |
32 | 5.4 | 73 | 5.9 |
33 | 3.9 | 74 | 2.7 |
34 | 5.9 | 75 | 32 |
35 | 1.1 | 76 | 51.9 |
36 | 1.9 | 77 | 7.2 |
37 | 1.2 | 78 | 8.5 |
38 | 3.7 | D1 | 49.1 |
39 | 2.5 | D2 | 114 |
40 | 2.3 | D3 | 1431 |
41 | 7.5 |
Claims (15)
- 一种通式(I)所示的化合物、其互变异构体、氘代物或药用盐:其中,Q为链状或环状不饱和基团,Q选自=CH 2、C 2-6烯基、C 2-6炔基或环A;所述=CH 2任选地被1个或多个R 5所取代;所述C 2-6烯基、C 2-6炔基任选地被1个或多个选自R 5和环A的取代基所取代;环A选自C 6-14芳基或5-14元杂芳基;所述C 6-14芳基或5-14元杂芳基任选地被1个或多个R 6所取代;R 1各自独立地选自H、卤素、氰基、C 1-3烷基、C 1-3烷氧基或C 1-3卤代烷基,优选为H;R 2选自H、卤素、氰基、取代或未取代的C 1-3烷基、取代或未取代的C 1-3烷氧基、取代或未取代的C 2-4烯基、取代或未取代的C 2-4炔基;R 4选自H、卤素或甲基;R 5各自独立地选自H、氰基、卤素、C 1-6烷基、C 1-6卤代烷基、-C 0-6亚烷基-OR a、-C 0-6亚烷基-OC(O)N(R a) 2、-C 0-6亚烷基-N(R a) 2、-C 0-6亚烷基-NR aC(O)R a、-C 0-6亚烷基-NR aC(O)N(R a) 2、-C 0-6亚烷基-NR aS(O)R a、-C 0-6亚烷基-NR aS(O) 2R a、-C 0-6亚烷基-S(=O)R a、-C 0-6亚烷基-S(=O) 2R a、-C 0-6亚烷基-SR a、-C 0-6亚烷基-S(R a) 5、-C 0-6亚烷基-C(=O)R a、-C 0-6亚烷基-C(=O)OR a、-C 0-6亚烷基-C(=O)N(R a) 2、-C 0-6亚烷基-C 3-14环烷基、-C 0-6亚烷基-(3-14元杂环基),所述C 1-6烷基、-C 0-6亚烷基-C 3-14环烷基或-C 0-6亚烷基-(3-14元杂环基)任选地还可被1个或多个R a所取代;R 6选自H、氰基、卤素、C 1-6烷基、C 1-6卤代烷基、-C 0-6亚烷基-OR a、-C 0-6亚烷基-OC(O)N(R a) 2、-C 0-6亚烷基-N(R a) 2、-C 0-6亚烷基-NR aC(O)R a、-C 0-6亚烷基-NR aC(O)N(R a) 2、-C 0-6亚烷基-NR aS(O)R a、-C 0-6亚烷基-NR aS(O) 2R a、-C 0-6亚烷基-S(=O)R a、-C 0-6 亚烷基-S(=O) 2R a、-C 0-6亚烷基-SR a、-C 0-6亚烷基-S(R a) 5、-C 0-6亚烷基-C(=O)R a、-C 0-6亚烷基-C(=O)OR a、-C 0-6亚烷基-C(=O)N(R a) 2、C 2-6烯基、C 2-6炔基、-C 0-6亚烷基-C 3-14环烷基、-C 0-6亚烷基-(3-14元杂环基)、-C 0-6亚烷基-C 6-14芳基或-C 0-6亚烷基-(5-14元杂芳基),所述C 1-6烷基、C 2-6烯基、C 2-6炔基、-C 0-6亚烷基-C 3-14环烷基、-C 0-6亚烷基-(3-14元杂环基)、-C 0-6亚烷基-C 6-14芳基或-C 0-6亚烷基-(5-14元杂芳基)任选地还可被1个或多个R a所取代;每个R a各自独立地选自H、卤素、羟基、氨基、氧代基、硝基、氰基、羧基、C 1-6烷基、C 1-6羟基烷基、C 1-6氨基烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6卤代烷氧基、C 1-6杂烷基、C 3-8环烷基、3-8元杂环基、C 6-14芳基或5-14元杂芳基;m选自0、1、2、3或4;n选自0或1;
- 根据权利要求1所述的化合物、其互变异构体、氘代物或药用盐,其特征在于,选自式(IA)或式(IA-1)化合物:其中,L选自键、C 2-6烯基或C 2-6炔基;所述C 2-6烯基或C 2-6炔基任选地被1个或多个R 5所取代;R 5各自独立地选自H、氰基、卤素、C 1-6烷基、C 1-6卤代烷基、-C 0-6亚烷基-OR a、-C 0-6亚烷基-OC(O)N(R a) 2、-C 0-6亚烷基-N(R a) 2、-C 0-6亚烷基-NR aC(O)R a、-C 0-6亚烷基-NR aC(O)N(R a) 2、-C 0-6亚烷基-NR aS(O)R a、-C 0-6亚烷基-NR aS(O) 2R a、-C 0-6亚烷基-S(=O)R a、-C 0-6亚烷基-S(=O) 2R a、-C 0-6亚烷基-SR a、-C 0-6亚烷基-S(R a) 5、-C 0-6亚烷基-C(=O)R a、-C 0-6亚烷基-C(=O)OR a、-C 0-6亚烷基-C(=O)N(R a) 2、-C 0-6亚烷基-C 3-14环烷基、-C 0-6亚烷基-(3-14元杂环基),所述C 1-6烷基、-C 0-6亚烷基-C 3-14环烷基或-C 0-6亚烷基-(3-14元杂环基)任选地还可被1个或多个R a所取代;环A选自C 6-14芳基或5-14元杂芳基,所述C 6-14芳基或5-14元杂芳基任选地被1个或多个R 6所取代;R 6选自H、氰基、卤素、C 1-6烷基、C 1-6卤代烷基、-C 0-6亚烷基-OR a、-C 0-6亚烷基-OC(O)N(R a) 2、-C 0-6亚烷基-N(R a) 2、-C 0-6亚烷基-NR aC(O)R a、-C 0-6亚烷基-NR aC(O)N(R a) 2、-C 0-6亚烷基-NR aS(O)R a、-C 0-6亚烷基-NR aS(O) 2R a、-C 0-6亚烷基-S(=O)R a、-C 0-6亚烷基-S(=O) 2R a、-C 0-6亚烷基-SR a、-C 0-6亚烷基-S(R a) 5、-C 0-6亚烷基-C(=O)R a、-C 0-6亚烷基-C(=O)OR a、-C 0-6亚烷基-C(=O)N(R a) 2、C 2-6烯基、C 2-6炔基、-C 0-6亚烷基-C 3-14环烷基、-C 0-6亚烷基-(3-14元杂环基)、-C 0-6亚烷基-C 6-14芳基或-C 0-6亚烷基-(5-14元杂芳基),所述C 1-6烷基、C 2-6烯基、C 2-6炔基、-C 0-6亚烷基-C 3-14环烷基、-C 0-6亚烷基-(3-14元杂环基)、-C 0-6亚烷基-C 6-14芳基或-C 0-6亚烷基-(5-14元杂芳基)任选地被1个或多个R a所取代;每个R a各自独立地选自H、卤素、羟基、氨基、氧代基、硝基、氰基、羧基、C 1-6烷基、C 1-6羟基烷基、C 1-6氨基烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6卤代烷氧基、C 1-6杂烷基、C 3-8环烷基、3-8元杂环基、C 6-14芳基或5-14元杂芳基;R 2选H、卤素、氰基、C 1-3烷基、C 1-3烷氧基、C 1-3卤代烷氧基、C 2-4烯基或C 2-4炔基;R 4选自H、卤素或甲基。
- 根据权利要求2中所述的化合物、其互变异构体、氘代物或药用盐,其特征在于,L选自键、乙烯基或乙炔基,所述乙烯基或乙炔基任选地被1个或多个R 5所取代;优选L选自键、乙烯基或乙炔基,更优选L为键。
- 根据权利要求1-3中任一项所述的化合物、其互变异构体、氘代物或药用盐,其特征在于,R 5独立地选自H、氰基、卤素、C 1-6烷基、C 1-6卤代烷基、-OR a、-OC(O)N(R a) 2、-N(R a) 2、-NR aC(O)R a、-NR aC(O)N(R a) 2、-NR aS(O)R a、-NR aS(O) 2R a、-S(=O)R a、-S(=O) 2R a、-SR a、-S(R a) 5、-C(=O)R a、-C(=O)OR a、-C(=O)N(R a) 2、-C 3-14环烷基或3-14元杂环基,所述每个R a独立地选自H、C 1-6烷基、C 1-6卤代烷基、C 1-6杂烷基、C 3-8环烷基、3-8元杂环基、C 6-14芳基或5-14元杂芳基;优选R 5独立地选自H、卤素、氰基、氨基、羟基、C 1-6烷基、C 1-6烷氧基、C 1-6卤代烷基、C 1-6卤代烷氧基、-S-C 1-6烷基、C 3-8环烷基或3-8元杂环基。
- 根据权利要求1-5中任一项所述的化合物、其互变异构体、氘代物或药用盐,其特征在于,R 6选自H、氰基、卤素、C 1-6烷基、C 1-6卤代烷基、-OR a、-OC(O)N(R a) 2、-N(R a) 2、-NR aC(O)R a、-NR aC(O)N(R a) 2、-NR aS(O)R a、-NR aS(O) 2R a、-S(=O)R a、-S(=O) 2R a、-SR a、-S(R a) 5、-C(=O)R a、-C(=O)OR a、-C(=O)N(R a) 2、C 2-6烯基、C 2-6炔基、-C 3-14环烷基、3-14元杂环基、-C 6-14芳基或5-14元杂芳基,所述每个R a独立地选自H、C 1-6烷基、C 1-6杂烷基、C 3-8环烷基、3-8元杂环基、C 6-14芳基或5-14元杂芳基;优选R 6选自H、卤素、氰基、C 1-3烷基、C 1-3烷氧基、C 1-3卤代烷基或-CHO,更优选R 6选自H、氟、氯、氰基、甲氧基或甲基。
- 根据权利要求1-7中任一项所述的化合物、其互变异构体、氘代物或药用盐,其特征在于,R 2选自H、卤素、氰基、C 1-3烷基、C 1-3烷氧基或乙烯基,优选H、氯、氰基、甲基、甲氧基或乙烯基,更优选氯、氰基、甲基或甲氧基。
- 根据权利要求1-8中任一项所述的化合物、其互变异构体、氘代物或药用盐,其特征在于,R 4为H。
- 一种药物组合物,其特征在于,所述药物组合物含有治疗有效量的权利要求1-10中任一项所述的化合物、其互变异构体、氘代物或药用盐和至少一种药学上可接受的辅料。
- 权利要求1-10任一项所述的化合物、其互变异构体、氘代物或药用盐或权利要求11所述的药物组合物在制备药物中的应用;优选在制备癌症治疗药物中的应用。
- 一种治疗和/或预防疾病的方法,包括向治疗对象施用治疗有效量的权利要求1-10任一项所述的化合物或权利要求11所述的药物组合物;优选治疗和/或预防癌症的方法。
- 一种药物组合,所述药物组合含有权利要求1-10任一项所述的化合物、其互变异构体、氘代物或药用盐和抗PD-L(1)抗体。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21865940.7A EP4212524A1 (en) | 2020-09-08 | 2021-09-06 | Cd73 inhibitor and application thereof in medicine |
CN202180054748.8A CN116348118A (zh) | 2020-09-08 | 2021-09-06 | Cd73抑制剂及其在医药上的应用 |
AU2021341258A AU2021341258A1 (en) | 2020-09-08 | 2021-09-06 | CD73 inhibitor and application thereof in medicine |
US18/044,049 US20230321100A1 (en) | 2020-09-08 | 2021-09-06 | Cd73 inhibitor and application thereof in medicine |
CA3191829A CA3191829A1 (en) | 2020-09-08 | 2021-09-06 | Cd73 inhibitor and application thereof in medicine |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010934821 | 2020-09-08 | ||
CN202010934821.8 | 2020-09-08 | ||
CN202011396364.8 | 2020-12-03 | ||
CN202011396364 | 2020-12-03 | ||
CN202110172897.6 | 2021-02-08 | ||
CN202110172897 | 2021-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022052886A1 true WO2022052886A1 (zh) | 2022-03-17 |
Family
ID=80632620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/116696 WO2022052886A1 (zh) | 2020-09-08 | 2021-09-06 | Cd73抑制剂及其在医药上的应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230321100A1 (zh) |
EP (1) | EP4212524A1 (zh) |
CN (1) | CN116348118A (zh) |
AU (1) | AU2021341258A1 (zh) |
CA (1) | CA3191829A1 (zh) |
TW (1) | TW202220976A (zh) |
WO (1) | WO2022052886A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023169327A1 (zh) * | 2022-03-07 | 2023-09-14 | 贝达药业股份有限公司 | 一种哒嗪类衍生物的晶型、制备方法及其应用 |
CN116874405A (zh) * | 2023-06-27 | 2023-10-13 | 山东轩硕医药科技有限公司 | 一种作为免疫调节剂的吲哚类化合物及其制备方法和用途 |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017120508A1 (en) * | 2016-01-08 | 2017-07-13 | Arcus Biosciences, Inc. | Modulators of 5'-nucleotidase, ecto and the use thereof |
WO2019168744A1 (en) | 2018-03-01 | 2019-09-06 | Eli Lilly And Company | Cd73 inhibitors |
WO2021041319A1 (en) * | 2019-08-29 | 2021-03-04 | Eli Lilly And Company | Crystalline forms of a cd73 inhibitor |
-
2021
- 2021-09-06 EP EP21865940.7A patent/EP4212524A1/en active Pending
- 2021-09-06 TW TW110133052A patent/TW202220976A/zh unknown
- 2021-09-06 CA CA3191829A patent/CA3191829A1/en active Pending
- 2021-09-06 US US18/044,049 patent/US20230321100A1/en active Pending
- 2021-09-06 CN CN202180054748.8A patent/CN116348118A/zh active Pending
- 2021-09-06 WO PCT/CN2021/116696 patent/WO2022052886A1/zh unknown
- 2021-09-06 AU AU2021341258A patent/AU2021341258A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017120508A1 (en) * | 2016-01-08 | 2017-07-13 | Arcus Biosciences, Inc. | Modulators of 5'-nucleotidase, ecto and the use thereof |
WO2019168744A1 (en) | 2018-03-01 | 2019-09-06 | Eli Lilly And Company | Cd73 inhibitors |
WO2021041319A1 (en) * | 2019-08-29 | 2021-03-04 | Eli Lilly And Company | Crystalline forms of a cd73 inhibitor |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023169327A1 (zh) * | 2022-03-07 | 2023-09-14 | 贝达药业股份有限公司 | 一种哒嗪类衍生物的晶型、制备方法及其应用 |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
CN116874405A (zh) * | 2023-06-27 | 2023-10-13 | 山东轩硕医药科技有限公司 | 一种作为免疫调节剂的吲哚类化合物及其制备方法和用途 |
CN116874405B (zh) * | 2023-06-27 | 2024-02-20 | 山东轩硕医药科技有限公司 | 一种作为免疫调节剂的吲哚类化合物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
US20230321100A1 (en) | 2023-10-12 |
TW202220976A (zh) | 2022-06-01 |
CA3191829A1 (en) | 2022-03-17 |
AU2021341258A1 (en) | 2023-04-13 |
CN116348118A (zh) | 2023-06-27 |
EP4212524A1 (en) | 2023-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI787018B (zh) | 轉染過程重排之抑制劑 | |
WO2022052886A1 (zh) | Cd73抑制剂及其在医药上的应用 | |
KR102194646B1 (ko) | 암 치료를 위한 피리미딘-2,4-다이아민 유도체 | |
TW426666B (en) | Sulfonamide compounds and pharmaceutical use thereof | |
CN110248940B (zh) | 芳基烃受体(AhR)调节剂化合物 | |
WO2016127074A1 (en) | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors | |
WO2022166974A1 (zh) | 吡啶并嘧啶酮类衍生物及其制备方法和用途 | |
WO2020011246A1 (zh) | 含苯环的化合物、其制备方法及应用 | |
CN101605783A (zh) | 作为药物、药物组合物尤其作为ikk抑制剂的新型n,n’-2,4-二苯胺基嘧啶衍生物及其制备 | |
CN103124730A (zh) | 杂环炔苯类化合物及其药用组合物和应用 | |
WO2017084640A1 (zh) | 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用 | |
CN106905316A (zh) | 蛋白激酶抑制剂 | |
WO2020107987A1 (zh) | 含异吲哚啉酮的erk抑制剂及其制备方法与用途 | |
WO2023072188A1 (zh) | Kras g12d抑制剂及其在医药上的应用 | |
WO2020233641A1 (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
CN104736533A (zh) | Vegfr3抑制剂 | |
CN114685460A (zh) | Kras g12c抑制剂及其在医药上的应用 | |
WO2022194066A1 (zh) | Kras g12d抑制剂及其在医药上的应用 | |
WO2023280283A1 (zh) | 用作shp2抑制剂的化合物及其应用 | |
CN109180681A (zh) | 一种dna毒性二聚体化合物 | |
WO2022017408A1 (zh) | 芳胺类衍生物及其制备方法和医药用途 | |
WO2022007677A1 (zh) | Cd73抑制剂及其在医药上的应用 | |
CN113173924B (zh) | 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途 | |
WO2022007966A1 (zh) | Pb2抑制剂及其制备方法和用途 | |
WO2022135590A1 (zh) | 一类嘧啶并杂环类化合物、制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21865940 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3191829 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021341258 Country of ref document: AU Date of ref document: 20210906 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021865940 Country of ref document: EP Effective date: 20230411 |